HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aminothiadiazole (NSC #4728) in patients with advanced cervical carcinoma. A phase II study of the Gynecologic Oncology Group.

Abstract
Twenty-one evaluable patients with advanced squamous-cell cervical cancer were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly. Nineteen had prior chemotherapy. One patient had a partial response; six had stable disease; 14 had increasing disease; and two were unevaluable for response. There was a single life-threatening toxic episode. Aminothiadiazole used in this dosage and schedule has minimal activity in previously treated cervical carcinoma patients.
AuthorsR F Asbury, J A Blessing, R Mortel, H D Homesley, J Malfetano
JournalAmerican journal of clinical oncology (Am J Clin Oncol) Vol. 10 Issue 4 Pg. 299-301 (Aug 1987) ISSN: 0277-3732 [Print] United States
PMID3618541 (Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • Thiadiazoles
  • 2-amino-1,3,4-thiadiazole
Topics
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma, Squamous Cell (drug therapy)
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Humans
  • Infusions, Intravenous
  • Thiadiazoles (administration & dosage, adverse effects, therapeutic use)
  • Uterine Cervical Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: